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Abstract
Purpose: With the current use of biologics in rheumatoid arthritis (RA), there is a need to monitor ongoing structural joint
damage due to the dissociation of articular cartilage damage from disease activity of RA. This study longitudinally analyzed
levels of serum cartilage biomarkers during 54 weeks of infliximab therapy, to evaluate the feasibility of biomarkers for
monitoring structural joint damage.
Methods: Subjects comprised 33 patients with early RA and 33 patients with established RA. All patients received 3 mg/kg
of infliximab and methotrexate for 54 weeks. Levels of the following serum cartilage markers were measured at baseline and
at weeks 14, 22, and 54: hyaluronan (HA); cartilage oligometric matrix protein (COMP); type II collagen (CII)-related
neoepitope (C2C); type II procollagen carboxy-propeptide (CPII); and keratin sulfate (KS). Time courses for each biomarker
were assessed, and relationships between these biomarkers and clinical or radiographic parameters generally used for RA
were investigated.
Results: Levels of CRP, MMP-3, DAS28-CRP, and annual progression of TSS were improved to similar degrees in both groups
at week 54. HA and C2C/CPII were significantly decreased compared to baseline in the early RA group (p,0.001), whereas
HA and COMP, but not C2C/CPII, were decreased in the established RA group. Strikingly, serum C2C/CPII levels were
universally improved in early RA, regardless of EULAR response grade. Both DHA and DC2C/CPII from baseline to week 54
correlated significantly with not only DCRP, but also DDAS28 in early RA. Interestingly, when partial correlation coefficients
were calculated by standardizing CRP levels, the significant correlation of DHA to DDAS28 disappeared, whereas
correlations of DC2C/CPII to DDAS28, DJNS, and DHAQ remained significant. These results suggest a role of DC2C/CPII as a
marker of ongoing structural joint damage with the least association with CRP, and that irreversible cartilage damage in
established RA limits restoration of the C2C/CPII level, even with tight control of joint inflammation.
Conclusion: The temporal course of C2C/CPII level during anti-TNF therapy indicates that CII turnover shifts toward CII
synthesis in early RA, but not in established RA, potentially due to irreversible cartilage damage. DC2C/CPII appears to offer
a useful marker reflecting ongoing structural joint damage, dissociated from inflammatory indices such as CRP and MMP-3.
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Introduction
Anti-tumor necrosis factor (TNF) therapy is considered the
global standard in the treatment of rheumatoid arthritis (RA),
originally with the purpose of achieving clinical remission and now
extending to structural remission at the radiographic level.
Mounting evidence has accumulated that anti-TNF therapy not
only inhibits radiographic progression of joint space narrowing,
but also promotes joint space widening, particularly in patients
with early RA, in whom annual changes in total modified van der
Heijde (vdH)-Sharp score (TSS) are negative [1,2]. These
observations allow clinicians to expect that TNF-blockade is
capable of regenerating cartilage. However, 2-dimensional radio-
graphic assessments based on TSS have not yet confirmed whether
ongoing cartilage damage can be precisely evaluated. Ultrasonog-
raphy and magnetic resonance imaging have recently been
reported to allow detection of subclinical joint damage in patients
showing clinical remission, suggesting a dissociation between
clinical remission and structural joint deterioration [2,3]. Alterna-
tive tools that can assess ongoing joint destruction more easily than
these imaging modalities should facilitate the evaluation of anti-
rheumatic therapy with the potential to target structural remission.
Molecular-marker technology (i.e., biomarkers) reportedly offer
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37447greater reliability and sensitivity than 2-dimensional radiography
in clinical applications [4–6] and may offer a potential alternative
to evaluate ongoing cartilage destruction in RA.
Alteration of articular cartilage turnover under arthritic
conditions finally depends on the balance between the synthesis
and degradation of cartilage matrix [7,8]. This can be
monitored by measuring cartilage-derived synthesis and degra-
dation molecules released into biological fluids, such as synovial
fluid, serum and urine. These cartilage-derived biomarkers have
been shown to reflect structural joint damage in RA and allow
assessment of therapeutic efficacy in candidate anti-rheumatoid
therapy. Existing biomarkers include cartilage oligometric
matrix protein (COMP), human cartilage glycoprotein-39
(YKL-40), type II collagen (CII)-related neoepitope (C2C),
carboxy-terminus of three-quarter peptide from cleavage of type
I collagen and CII (C1,2C), type II procollagen carboxy-
propeptide (CPII), C-telopeptide of type II collagen (CTX-II),
keratin sulfate (KS-5D4), and aggrecan neoepitope (CS-846).
Although controversy remains about which of the biological
fluids offers the best sampling source and about diurnal and
activity-related variations in each biomarker [9], a fundamental
principle is that markers for cartilage degradation generally
increase with the progression of joint destruction, whereas
markers for cartilage synthesis increase following successful
treatment with anti-TNF therapy [10]. The current use of
biologics in RA makes it increasingly important to identify
useful and simple blood tests that can precisely reflect responses
to treatment, particularly in terms of cartilage turnover and
systemic inflammation resulting from RA.
Despite the advantages of technical simplicity, the practical
application of serum cartilage-derived biomarkers to date has
remained limited. This is due, in part, to the fact that
superiority over traditional laboratory markers has not been
studied in a longitudinal fashion. The present study analyzed
time courses for serum levels of cartilage markers during 54
weeks of infliximab therapy in two different cohorts of early and
established RA, and compared the results with other laboratory,
clinical and radiographic parameters generally used for RA.
This study also estimated the feasibility of using cartilage
biomarkers as a potential indicator of structural joint deterio-
ration in RA.
Materials and Methods
All study protocols were approved by the institutional review
board at Saitama Medical Center. All participants were informed
about the goals and methods of the study and written consent was
obtained prior to enrolment.
Patients
In this study, a total of 66 patients were enrolled from the
Division of Rheumatology and Clinical Immunology at Saitama
Medical Center, and all patients fulfilled the diagnostic criteria for
RA according to American College of Rheumatology criteria [11].
Thirty-three patients with arthritis symptoms of ,9 months
duration were classified as having early RA, and 33 patients with
disease duration .10 years were classified as showing established
RA. Baseline characteristics of patients are shown in Table 1. All
patients had clinically active disease, despite administration of
conventional first-level disease-modifying anti-rheumatic drugs,
and the mean 28-joint disease activity score (DAS28)-CRP at
baseline was 5.24 for early RA and 4.8 for established RA. The
rate of anti-cyclic citrullinated peptide (anti-CCP) antibody was
82% (27 patients) for the early RA group and 85% (28 patients) for
the established RA group. Infliximab was administered at 3 mg/
kg dose in weeks 0, 2, and 6, and then every 8 weeks. MTX was
concomitantly administered at 6–10 mg/week in all patients.
Patients were allowed to continue use of non-steroidal anti-
inflammatory drugs and oral glucocorticoids (prednisolone-equiv-
alents ,10 mg/day) that they had been taking at study entry.
Patients were evaluated for therapeutic response at baseline and
14, 22, and 54 weeks after starting infliximab. At each evaluation,
blood samples were obtained and sera were separated and stored
at 280uC until needed for biomarker analysis.
Clinical evaluation of therapeutic response
The following clinical and laboratory parameters were longitu-
dinally examined in each patient: CRP; stromelysin 1 (MMP-3);
modified Health Assessment Questionnaire (HAQ) score; and
DAS28-CRP. Scores for DAS28-CRP are reportedly lower than
the original DAS28 assessments using the erythrocyte sedimenta-
tion rate [12] and were defined as follows: $4.1, high activity;
$2.7 to ,4.1, moderate activity; $2.3 to ,2.7, low activity; and
,2.3, remission. In terms of radiographic analysis, radiographs of
Table 1. Baseline characteristics of the patients with early and established RA enrolled in this study*.
Early RA (,9 months) Established RA (.10 yrs)
No. of patients 33 33
Mean age 46.2 (19–75) 55.6 (34–80)
Gender (male/female) 10/23 6/27
Disease duration [months] 5.5 (2–9) 285 (122–516)
Swollen joint counts 10.3 (3–25) 10.3 (0–23)
Tender joint counts 8.8 (1–24) 8.6 (0–27)
CRP [mg/dl] 4.3 (0.2–11.0) 3.2 (0.1–10.9)
MMP-3 [ng/ml] 367 (31–1378) 302 (37–1292)
Rate of anti-CCP antibody [%] 82 85
DAS28-CRP 5.24 (3.11–7.75) 4.8 (2.54–6.83)
HAQ score 1.68 (0.75–2.38) 2.12 (0.75–3.00)
corticosteroid administration [%(cases)] 9 (3) 18 (6)
*Except where indicated otherwise, values are expressed as the mean (range).
doi:10.1371/journal.pone.0037447.t001
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patients in the early RA group and 23 patients in the established
RA group. Two expert readers independently scored articular
damage and progression in a blinded fashion according to the
modified vdH-Sharp scoring method. Progression of TSS from
baseline to week 54 (DTSS) was determined, and the proportion of
patients with DTSS#0 was calculated.
Cartilage biomarker analyses
The neoepitope resulting from collagenase cleavage of CII (i.e.,
C2C) and the c-propeptide cleaved from procollagen type II (i.e.,
CPII) were used as indicators of the degradation and synthesis of
CII, respectively. Serum levels of each marker were measured
using enzyme-linked immunosorbent assay (ELISA) (IBEX Tech-
nologies, Montreal, Quebec, Canada). The ratio C2C/CPII was
used as an indicator of CII turnover, as previously reported
[13,14]. Serum COMP levels were determined by sandwich
ELISA (BioVendor Laboratory, Brno, Czech Republic), using 2
monoclonal antibodies against separate antigenic determinants of
human COMP molecules. Serum HA levels were determined
using an HA Assay Kit (IBA method; Seikagaku, Tokyo, Japan)
utilizing HA-binding protein. KS was determined by high-
performance liquid chromatography (HPLC) after digestion with
keratanase II (Seikagaku), as reported previously [15,16]. Serum
samples were treated with actinase E (Kaken Pharmaceutical,
Tokyo, Japan) and the negatively charged substance containing
KS was fractionated by Q sepharose and digested by keratanase II.
These sequential enzymatic digestions yielded KS-derived b-
galactosyl-(1–4)-6-O-sulfo-N-acetylglucosamine (m-ks) and b-6-O-
sulfo-garactosyl-(1–4)-6-O-sulfo-N-acetylglucosamine (d-ks), which
were measured using HPLC. Total KS was calculated as the sum
of m-ks and d-ks values.
Statistical analysis
Analysis of our data revealed that most of the clinical,
radiographic, and laboratory results were non-parametric. Statis-
tical comparisons of laboratory parameters or cartilage biomarker
levels at each time point with those at baseline were performed
using Wilcoxon’s matched-pairs signed-ranks test (two-tailed).
Spearman’s rank correlation coefficient was used to analyze
relationships between changes in individual biomarkers and
changes in laboratory or functional or radiographic parameters
of RA. To remove the effects of decreased inflammation (i.e., CRP
level) resulting from anti-TNF therapy on cartilage turnover,
partial correlation coefficients controlling for CRP level were
calculated to examine the relationship between cartilage biomark-
ers and measures of RA disease activity. Subgroup analysis was
conducted based on European League of Associations for
Rheumatology (EULAR) response criteria, such as good response,
moderate response, and no response. As an indicator of CII
turnover, C2C/CPII ratios in each response group were analyzed
longitudinally, and changes from baseline to week 54 (i.e., C2C/
CPII improvement) were compared between the three subgroups
using the Kruskal-Wallis test. Statistical analyses were performed
using SPSS version 17.0 software (SPSS, Chicago, IL). Values of
p,0.05 were considered significant.
Sample size analysis for Wilcoxon’s signed-ranks test was
performed to demonstrate differences between serum level at
baseline and at week 54 under the effect size given in each
biomarker or laboratory index. In post-hoc analysis for early RA,
11, 60, 8, 5, 13, and 22 patients would be required to demonstrate
a difference with an alpha level of 0.05 and 80% power, for C2C/
CPII, HA, CRP, DAS28, MMP3, and HAQ, respectively.
Similarly, for established RA, 29, 30, 20, 13, 7, and 18 patients
would be required to demonstrate a difference, with an alpha level
of 0.05 and 80% power, for KS, HA, COMP, CRP, DAS28, and
MMP3, respectively. Sample sizes for correlation analysis were
also analyzed to detect a moderate to large correlation coefficient
(r.0.4) that was significantly different from the presence of no
correlation (r=0) with an alpha level of 0.05 and 80% power. In
post-hoc analysis for early RA at week 54, 29 and 26 patients
would be required to represent a given bivariate correlation
coefficient with 80% power for DC2C/DCPII vs. DCRP and
DC2C/DCPII vs. DDAS28, respectively. Similarly, 31 patients
would be required to detect a given partial correlation coefficient
with 80% power for DC2C/DCPII vs. DDAS28. In the established
RA at week 54, 27 and 20 patients would be required to represent
a given bivariate correlation coefficient with 80% power for
DC2C/DCPII vs. DJNS and DC2C/DCPII vs. DHAQ, respec-
tively. Regarding the partial correlation coefficient, 31 patients
each would be required both for DC2C/DCPII vs. DJNS and for
DC2C/DCPII vs. DHAQ. Taken together with these data, the
projected sample size offering sufficient statistical power was 30
patients each in the early and established RA groups.
Results
Clinical evaluation
Of the 33 patients in the early RA group, 1 patient achieved
clinical remission and 1 patient exhibited secondary loss of efficacy
after 6-month infliximab therapy. These 2 patients discontinued
infliximab, and the latter patient switched to tocilizumab. One
patient experienced anaphylactic reaction at week 38 and switched
to etanercept. Overall, 3 patients withdrew from the study, and the
remaining 30 patients in the early RA group completed 54 weeks
of infliximab therapy. In the established RA group, 5 patients
exhibited secondary loss of efficacy and switched to etanercept
(n=3) or tocilizumab (n=2). One patient discontinued infliximab
at week 22, because she was planning to become pregnant.
Overall, 6 patients were excluded and the remaining 27 patients in
the established RA group completed 54 weeks of infliximab
therapy.
As expected, laboratory indices for RA disease activity, such as
CRP, MMP-3 and DAS28-CRP, had decreased significantly by
week 54 in both groups (Table 2). The decrease in DAS28-CRP
was prominent in patients with early RA, with mean score at week
54 below the level of clinical remission. Mean HAQ score was
significantly decreased at week 54 in the early RA group, but
remained unchanged in the established RA group. When DAS28-
CRP scores were assessed using EULAR response criteria, 90%
and 78% of patients were categorized as showing good or
moderate response in the early and established RA groups,
respectively, with no significant difference apparent between
groups. Radiographic structural assessment using the TSS
revealed that mean DTSS per year (annual progression) was 3.7
in the early RA group and 4.0 in the established RA group, while
the proportion with DTSS#0 exceeded 70% in both groups,
suggesting that our clinical study using infliximab yielded
successful clinical results comparable to those in a previous study
in Japan [17].
Temporal changes in cartilage biomarkers during 54-
week infliximab therapy
In the early RA group, serum levels of HA and C2C/CPII
gradually decreased over time during 54-week infliximab therapy,
and levels of HA at weeks 14, 22 and 54, and C2C/CPII at weeks
22 and 54 were significantly lower than each baseline level
(p,0.001). These two biomarkers appeared to synchronize with
Cartilage Biomarkers during Anti-TNF Therapy
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contrast, COMP level remained constant during infliximab
therapy (Table 3, Fig. 1A). Serum KS level slightly increased at
week 14, followed by a gradual decrease to the baseline level at
week 54. In the established RA group, serum level of HA was
significantly decreased at week 14 (p,0.05) and became constant,
demonstrating a quite similar pattern to that of CRP, whereas
C2C/CPII remained unchanged during 54 weeks (Table 3,
Fig. 1B). Level of serum COMP in established RA, which
demonstrated a higher baseline level than in early RA, gradually
decreased during the 54-week infliximab therapy with significant
differences at week 54 (p,0.05). In contrast, level of serum KS in
established RA, which also demonstrated a higher baseline level
than in early RA, gradually increased with significant differences
at weeks 22 and 54 compared to baseline (p,0.05).
Correlations between cartilage biomarkers and RA
disease activity markers
Correlations between levels of cartilage biomarkers and degree
of RA disease activity (e.g., CRP, MMP-3, and DAS-28),
radiographic progression (e.g., DJNS) and patient function (e.g.,
HAQ score) were investigated at weeks 22 and 54. Several marker
pairs with significant correlations are summarized in Table 4.
Among the four cartilage biomarkers tested, only C2C/CPII and
HA level yielded strong linear correlations with several disease
activity measures of RA. Since the degree of structural joint
damage, particularly in terms of cartilage destruction, is reportedly
dissociated from the degree of joint inflammation, the present
analysis focused on whether temporal changes in cartilage
turnover were associated with the degree of CRP decrement. In
the early RA group, DC2C/DCPII and DHA displayed significant
correlations with DCRP at both weeks 22 and 54. Correlation with
DDAS28 was observed at week 22 for DHA, and at both weeks 22
and 54 for DC2C/DCPII. Interestingly, according to partial
correlation coefficients, the significant correlation between DHA
and DDAS28 disappeared when the level of CRP was standard-
ized. In contrast, the significant correlation between DC2C/
DCPII and DDAS28 remained present even after standardization
of CRP levels. In the established RA group, DC2C/DCPII
correlated with neither DCRP nor DDAS28, whereas DHA did
correlate with DCRP at both weeks 22 and 54. Of note is the
finding that DC2C/DCPII significantly correlated with DJNS and
Table 2. Time-course changes in biochemical, clinical, radiographic, and functional measures during 1-year infliximab therapy.
Time after starting infliximab
0W (baseline) 14W 22W 54W
Early RA (n=30)
CRP [mg/dl] 4.12{ 1.43** 1.02** 0.45**
DAS28-CRP 5.16 3.13** 2.74** 2.2**
MMP-3 [ng/ml] 342 167 116* 105*
HAQ score{ 1.46 0.92** 0.9** 0.8**
TSS (SD) (n=26) 10.5 (18.7) n.d.*** n.d. 14.2 (20.1)
JNS (SD) (n=26) 4.8 (7.6) n.d. n.d. 7.2 (10.3)
DTSS (mean/median) 3.7/0
Rate of DTSS#0 [%(cases)] 73 (19)
EULAR category of response [% (cases)]
Good 63 (19)
Moderate 27 (8)
No response 10 (3)
Established RA (n=27)
CRP [mg/dl] 2.91 0.68** 0.66* 0.66*
DAS28-CRP 5.11 2.96** 2.76** 2.80**
MMP-3 [ng/ml] 298 92 98* 91*
HAQ score 1.88 1.7 1.71 1.73
TSS (SD) (n=23) 211.2 (90.2) n.d. n.d. 215.4 (96.3)
JNS (SD) (n=23) 85.8 (43.6) n.d. n.d. 88.1 (44.2)
DTSS (mean/median) 4.0/0
Rate of DTSS#0 [%(cases)] 70 (16)
EULAR category of response [% (cases)]
Good 41 (11)
Moderate 37 (10)
No response 22 (6)
{Except where indicated otherwise, values are expressed as the mean.
*p,0.05 versus baseline levels.
**p,0.001 versus baseline levels.
***n.d., not determined.
doi:10.1371/journal.pone.0037447.t002
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even after standardizing CRP level. These results suggest that
DHA preferentially correlated with the level of CRP, while
DC2C/DCPII represented a CRP-independent indicator of joint
destruction reflecting radiographic joint space narrowing and
patient function.
Association between balance of CII synthesis/
degradation and efficacy of infliximab
As C2C/CPII preferentially reflected joint damage independent
of changes in inflammatory indices, C2C/CPII was further
analyzed for relationships with EULAR response grade after 54
weeks of infliximab therapy. Strikingly, in the early RA group,
C2C/CPII was reduced (i.e., improved), regardless of responsive-
ness to infliximab, indicating that even in non-responders, the
balance of CII synthesis/degradation became shifted toward
synthesis (Fig. 2A). By contrast, C2C/CPII in the established RA
group universally increased (i.e., worsened), regardless of respon-
siveness to infliximab, indicating that the net balance of CII
synthesis/degradation was shifted toward degradation even in
good responders (Fig. 2B). For all patients, C2C/CPII in non-
responders was increased (i.e., worsened) compared to baseline,
whereas C2C/CPII in moderate or good responders was reduced
(i.e., improved) from baseline (Fig. 2C).
Discussion
RA is an inflammatory joint disease that predominantly involves
the synovial tissues of joints and is characterized by variable
disease onset and clinical course, ultimately resulting in structural
joint destruction and subsequent physical disability. Early treat-
ment with anti-TNF therapy is currently accepted as an effective
strategy to achieve clinical and structural remission, potentially
improving physical disability. In the present study, 54-week
treatment with infliximab achieved satisfactory results according
to the levels of CRP, MMP-3, and DAS28, EULAR response
criteria, and the rate of DTSS#0. Although these clinical
measures for RA were similarly improved in both early and
established RA, C2C/CPII as an indicator of CII turnover was
significantly improved from baseline in early RA, but not in
established RA. Strikingly, C2C/CPII was universally improved
and shifted toward CII regeneration in early RA, regardless of
EULAR response grade. In contrast, C2C/CPII was universally
shifted toward CII degradation in established RA, regardless of
Figure 1. Temporal course of cartilage biomarker levels during 54-week infliximab therapy. Data for each time point represent mean
levels of serum CRP, HA, COMP, KS, and C2C/CPII in early RA (A) and established RA (B). Standard deviation (SD) error bars are not plotted in these
graphs for clarity and are shown in Table 3. Statistical analyses were performed using Wilcoxon’s matched-pairs signed-ranks test, two-tailed. *p,0.05
versus level at baseline. **p,0.001 versus level at baseline.
doi:10.1371/journal.pone.0037447.g001
Table 3. Time-course changes in the levels of cartilage
biomarkers during 1-year infliximab therapy.
Time after starting infliximab
0W
(baseline) 14W 22W 54W
Early RA (n=30)
HA [ng/ml] 420 (923) { 306 (852)* 134 (166)* 81 (69)**
KS [mg/ml] 0.87 (0.30) 0.96 (0.37)* 0.90 (0.31) 0.85 (0.22)
COMP [ng/ml] 545 (297) 549 (237) 561 (232) 570 (239)
C2C [ng/ml] 229 (47) 204 (45) 171 (46)* 156 (46)**
CPII [ng/ml] 733 (304) 858 (437) 875 (416)* 997 (489)*
C2C/CPII 0.34 (0.17) 0.32 (0.16) 0.20 (0.04)** 0.17 (0.05)**
Established RA
(n=27)
HA [ng/ml] 335 (301) 199 (209)* 191 (196)* 193 (199)*
KS [mg/ml] 1.05 (0.34) 1.12 (0.43) 1.22 (0.38)* 1.25 (0.46)*
COMP [ng/ml] 845 (321) 788 (278) 734 (267) 669 (230)*
C2C [ng/ml] 224 (68) 231 (62) 211 (58) 264 (54)
CPII [ng/ml] 1039 (465) 1087 (439) 834 (306) 886 (243)*
C2C/CPII 0.28 (0.15) 0.27 (0.13) 0.3 (0.11) 0.31 (0.12)
{Values are expressed as mean (SD).
*p,0.05 versus baseline levels.
**p,0.001 versus baseline levels.
doi:10.1371/journal.pone.0037447.t003
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anti-TNF therapy should clearly be initiated while the patient is
still in the early phase, while the regenerative capacity of articular
cartilage is maintained and before irreversible structural joint
damage occurs. Past clinical trials, such as the Best study, have
demonstrated that patients initially treated with infliximab
exhibited persistent low disease activity even after the cessation
of infliximab, suggesting the clinical significance of early
introduction of aggressive treatment in early RA with poor
prognostic factors [18].
A noteworthy finding was that annual changes in cartilage
biomarker levels correlated with annual progression of joint
destruction and physical function after anti-TNF therapy. To the
best of our knowledge, no previous studies have provided such
insights. Significant correlations were found between DC2C/CPII
and DHAQ (r=0.58, p=0.02) and between DC2C/CPII and
DJNS (r=0.51, p=0.03) in our established RA cohort. The fact
that joint space narrowing on radiography largely reflects loss of
cartilage rather than bony erosion may explain the close
relationship between DJNS and DC2C/CPII. Although determin-
ing whether HAQ improvement is a cause or consequence of
decreased DC2C/CPII is difficult, one potential explanation for
this correlation is that high activity and subsequent mechanical
Table 4. Spearman’s correlation coefficients and partial correlation coefficients of cartilage markers vesus RA disease markers.
22W 54W
Spearman’s r partial r** Spearman’s r partial r
Early RA
DC2C/DCPII vs. DCRP 0.44 (0.02)* n.a." 0.50 (0.01) n.a.
vs. DDAS28 0.49 (0.03) 0.48 (0.04) 0.52 (0.01) 0.49 (0.02)
vs. DKS n.s. n.s.{ 20.46 (0.03) n.s.
DHA vs. DCRP 0.37 (0.04) n.a. 0.45 (0.03) n.a.
vs. DDAS28 0.52 (0.02) n.s. 0.43 (0.04) n.s.
vs. DMMP-3 0.63 (0.02) n.s. 0.74 (0.002) 0.48 (0.04)
Established RA
DC2C/DCPII vs. DCRP n.s. n.a. n.s. n.a.
vs. DDAS28 n.s. n.s. n.s. n.s.
vs. DKS n.s. n.s. 20.49(0.03) n.s.
vs.DJNS n.d. n.d.{ 0.51 (0.03) 0.48 (0.04)
vs.DHAQ n.d. n.d. 0.58 (0.02) 0.49 (0.03)
DHA vs. DCRP 0.56 (0.02) n.a. 0.43 (0.04) n.a.
vs. DDAS28 n.s. n.s. n.s. n.s.
vs. DMMP-3 0.49 (0.04) n.s. 0.51 (0.04) n.s.
*Values are correlation coefficients calculated using Spearman’s rank correlation. P values are expressed in parentheses. p,0.05 is considered as statistically significant.
**Partial correlation coefficients were obtained after controlling CRP level for each marker pair.
"n.a., not applicable.
{n.s., not significant.
{n.d., not determined.
doi:10.1371/journal.pone.0037447.t004
Figure 2. Improvement of C2C/CPII from baseline to week 54 was assessed in early RA (A), established RA (B), and all patients (C).
Data are expressed as mean (6 SD) percentage of baseline. Patients were divided into three subgroups according to the degree of clinical response
at week 54 using EULAR response criteria. Positive values signify that the balance of CII synthesis/degradation is biased toward synthesis, while
negative values indicate that the balance is biased toward degradation. Statistical analysis was performed using the Kruskal-Wallis test. *p,0.05.
doi:10.1371/journal.pone.0037447.g002
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CII turnover, as reported by Roos et al. [19].
Serum levels of KS have been reported as an indirect measure
of aggrecan turnover in articular cartilage and further analyzed for
a role as a predisposing factor for osteoarthritis (OA) with a
polyarticular, progressive phenotype [20]. KS level is elevated not
only in patients with cartilage degeneration, but also in healthy
individuals with higher sports activity [21], indicating that KS level
can universally elevate in cases with increased cartilage turnover,
even in normal cartilage. Wakitani et al. have reported that serum
KS level in the knee OA is elevated more in the early stage than in
the advanced stage, suggesting that KS reflects aggrecan turnover
rather than the degree of joint destruction [16]. Similarly, levels of
serum CS-846 epitope, as the marker for newly synthesized
aggrecan, have been shown to increase in slowly progressive RA
and signify an ability or attempt to repair damaged cartilage matrix
[22,23]. From this perspective, gradually increased KS turnover in
established RA was potentially attributable to not only persistent
aggrecan release from cartilage, but also the fact that newly
synthesized aggrecan cannot be incorporated into cartilage matrix
that has been inherently damaged at baseline. In cases of early RA,
KS levels were increased in week 14, but stabilized thereafter due to
the inhibitory effects of TNF blockade on cartilage degradation,
leading to normalization of cartilage turnover.
Contrasting results were obtained regarding the temporal course
of serum COMP levels between early and established RA.
Numerous studies have proposed the feasibility of serum COMP
levels in monitoring articular cartilage damage or predicting the
efficacy of anti-TNF therapy in RA [24–26]. In our established RA
cohort, serum COMP levels were high at baseline, and gradually
decreased during the course of infliximab therapy, as previously
reported [24]. However, in early RA, serum COMP levels at
baseline were low, and remained unchanged over 54-week
infliximab therapy, despite fully exertion of the therapeutic effects
of infliximab. Given the evidence that serum COMP levels elevate
with increasing physical activity [27], constant levels of COMP over
time in early RA might theoretically be explained if the decrement
in COMP levels induced by infliximab is balanced by increased
physical activity as evidenced from decreased HAQ scores.
Most measures of RA disease activity, such as the simplified
disease activity index, Boolean criteria, and DAS28, exhibit
correlations with CRP, because CRP is involved in each definition.
As for cartilage biomarkers, this study showed that DHA and
DC2C/CPII correlated significantly with not only DCRP, but also
DDAS28 in early RA. Interestingly, when partial correlation
coefficients were calculated by standardizing CRP levels, the
significant correlation of DHA with DDAS28 disappeared, whereas
correlations of DC2C/CPII with DDAS28,DJNS, and DHAQwere
still significant. These results suggest a role of DC2C/CPII as a
marker of ongoing structural joint damage with the least association
to markers for systemic inflammation, such as CRP and erythrocyte
sedimentation rate. Indeed, serum cytokine profile among the
patientswithestablishedRAinthisstudyrevealedthatlevelsofmost
inflammatory cytokines, including IL-6, TNF, and IL-17, were
decreasing with decreasing CRP level over 54-week of infliximab
therapy, whereas C2C/CPII level deteriorated over time (unpub-
lished data, Fig. S1).
Significant concerns remain as to the differences in cartilage
regenerative capacity between early and established RA. C2C/
CPII was universally improved and shifted toward CII regener-
ation in early RA, but not in established RA, regardless of
responsiveness to infliximab. Restoration of C2C/CPII balance
and the resulting cartilage regeneration is likely to be relevant to
the degree to which the cartilage matrix has been damaged before
starting anti-TNF therapy, rather than the magnitude of the
suppression of systemic inflammation during anti-TNF therapy. A
previous experimental study showed that mice with antigen- or
zymosan-induced arthritis displayed reversible cartilage damage
only when levels of collagen degradation were low [28]. This
finding was corroborated by a human study using cartilage
explants culture in vitro, in which aggrecanase-mediated aggrecan
degradation did not influence the regenerative capacity of
cartilage, but was markedly impaired after MMP-mediated
aggrecan and collagen type II degeneration were initiated [29].
MMP-mediated aggrecan and collagen type II degeneration might
thus represent a turning point for the reversibility of cartilage
degradation. Therefore, whether RA is in the early or established
phase (i.e., disease duration) does not appear critical.
In conclusion, DC2C/CPII offers a useful marker reflecting
ongoing cartilage damage, which appears dissociated from
inflammatory indices. As most measures of RA disease activity
generally correlate with CRP, C2C/CPII appears to be of great
clinical value as a CRP-independent marker, particularly when
ongoing structural joint damage is evaluated during biological
therapy in RA. The temporal course of C2C/CPII level during
anti-TNF therapy indicated that CII turnover shifted toward CII
synthesis in early RA, but not in established RA, potentially due to
irreversible cartilage damage. The clinical significance of C2C/
CPII should be further investigated in large-scale prospective
studies to evaluate the feasibility of using this ratio as a surrogate
marker for monitoring ongoing structural joint damage during the
course of anti-rheumatoid therapy.
Supporting Information
Figure S1 Temporal course of the serum levels of various
cytokines in patients with established RA during 54-week infliximab
therapy. The data were measured using a LuminexH multiplex
beads cytokine assay. Values were expressed as a proportion of each
baseline value. Of note is the finding that serum levels of most
inflammatory cytokines, including IL-6, TNF, and IL-17, were
decreasing with decreasing CRP level over 54-week of infliximab
therapy, whereas C2C/CPII level deteriorated over time.
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